We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
KineMed to Collaborate with Merck KgaA to Validate new Applications for Drug Development Candidates
News

KineMed to Collaborate with Merck KgaA to Validate new Applications for Drug Development Candidates

KineMed to Collaborate with Merck KgaA to Validate new Applications for Drug Development Candidates
News

KineMed to Collaborate with Merck KgaA to Validate new Applications for Drug Development Candidates

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "KineMed to Collaborate with Merck KgaA to Validate new Applications for Drug Development Candidates"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

KineMed, Inc. has announced that it will collaborate with Merck Serono, a division of Merck KgaA to discover new applications for drug candidates. KineMed's pathway-based drug discovery and development technology identifies compounds that can modulate key metabolic pathways present in both preclinical animal models and in humans.

By measuring real-time activity of drugs against these targeted pathways, KineMed's technology reduces development risk by selecting drug candidates with the best potential to demonstrate clinical efficacy and confirm desired drug activity in first-in-man studies.

In the collaboration, KineMed will identify new therapeutic utility in in vivo preclinical models by applying its proprietary translational medicine technologies. Once a disease target is established for a selected drug candidate, KineMed and Merck KGaA will jointly determine the best development and commercialization path for the development candidates being studied.

Under the terms of the agreement, KineMed will receive from Merck an upfront payment, milestones and royalty payments on products advanced with KineMed's technology. Additional terms of the deal were not disclosed.

David Fineman, President and CEO of KineMed, commented, "We are pleased to expand our relationship with Merck KGaA into this broader development collaboration. Our technology uniquely enables our partners to screen development candidates against KineMed's dynamic targets of pathway kinetics. Partnering with KineMed further enables its partners to rapidly demonstrate on-mechanism dose response in first-in-man studies with KineMed's unique translational medicine capabilities."

Mr. Fineman continued, "In this collaboration with Merck, KineMed will be using its technology to identify new therapeutic activities of pipeline compounds. The collaboration preserves KineMed's freedom to operate on its own development programs as well as partner with other companies in key disease indications."

Advertisement